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Volume changes in Alzheimer’s disease
and mild cognitive impairment: cognitive
associations
Abstract Objective: To assess the
relationship between MRI-derived
changes in whole-brain and ventricu-
lar volume with change in cognitive
scores in Alzheimer’s disease (AD),
mild cognitive impairment (MCI) and
control subjects. Material and
methods: In total 131 control, 231
MCI and 99 AD subjects from the
Alzheimer’s Disease Neuroimaging
Initiative (ADNI) cohort with T1-
weighted volumetric MRIs from
baseline and 12-month follow-up
were used to derive volume changes.
Mini mental state examination
(MMSE), Alzheimer’s disease
assessment scale (ADAS)-cog and
trails test changes were calculated
over the same period. Results: Brain
atrophy rates and ventricular enlarge-
ment differed between subject groups
(p<0.0005) and in MCI and AD were
associated with MMSE changes. Both
measures were additionally associated
with ADAS-cog and trails-B in MCI
patients, and ventricular expansion
was associated with ADAS-cog in
AD patients. Brain atrophy
(p<0.0005) and ventricular expansion
rates (p=0.001) were higher in MCI
subjects who progressed to AD within
12 months of follow-up compared
with MCI subjects who remained
stable. MCI subjects who progressed
to AD within 12 months had similar
atrophy rates to AD subjects.
Conclusion: Whole-brain atrophy
rates and ventricular enlargement
differed between patient groups and
healthy controls, and tracked disease
progression and psychological
decline, demonstrating their relevance
as biomarkers.
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Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia, estimated to affect 24 million people worldwide
[1]. AD is a neurodegenerative disorder which typically has
an insidious initial impairment in memory, extending to
multiple domains as the disease progresses [2]. This is
mirrored by pathology, with neurofibrillary tangles initially
being limited to the hippocampus and entorhinal cortex,
spreading to other limbic structures and eventually the
whole cerebral cortex [3].
Amnestic mild cognitive impairment (MCI) describes
subjects who show measurable memory deficits but do not
meet AD criteria [4]. MCI therefore represents an
opportunity to treat those who may progress to AD before
widespread cognitive deficits are manifest.
A characteristic macroscopic consequence of AD pa-
thology is brain atrophy, visible on MRI. At a group level
AD is associated with smaller brain volumes and larger
ventricles than healthy age-matched controls, while MCI
groups have intermediate volumes [5]. However, there is
overlap between these measures due to the natural variation
in cerebral volumes, morphology and physiological state at
the time of MRI. Rates of volume change may also
discriminate between groups, reflecting differences in rates
of neuronal degeneration.
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Although it is not possible to measure longitudinal
neuronal loss directly in vivo, change in cerebral volume
(atrophy rate) can be measured using MRI. This can either
be calculated indirectly using estimates of regional or
whole-brain volumes at two time points which requires two
measurements with associated errors (e.g. 12-month inter-
val), or by directly measuring volume change over time with
methods such as the boundary shift integral (BSI) which
requires one measure with associated error [6, 7]. Direct
methods have been shown to be more precise than indirect
methods [8]. Measures of volume loss from MRI have been
used to assess atrophy in AD [6, 9], and to differentiate MCI
and AD from controls [10–12]. Longitudinal studies show
normal controls to have age-related cerebral atrophy rates of
around 0.5% per year in subjects aged 65–75 [13, 14]; while
atrophy rates in AD are around 2% per year [15]. Rates of
brain atrophy and ventricular enlargement have also been
proposed as potential biomarkers of disease progression in
trials. We wished to measure rates of change in brain and
ventricular volumes and assess their relationship with
cognitive measures and clinical progression from MCI
to AD.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
is a multicentre study of AD and MCI patients and control
subjects who received clinical, neuropsychological and
imaging assessments at 6- or 12-month intervals (see http://
adni-info.org for full protocol). This study used baseline and
12-month assessments of ADNI subjects (a) to measure
whole-brain and ventricular change in (i) AD, (ii) MCI and
(iii) healthy age-matched controls; (b) to assess the associ-
ation of atrophy rates with cognitive change; and (c) to
compare brain atrophy and ventricular expansion rates in
MCI subjects who converted to AD within 12 months after
baseline, with those who remained stable over this period.
Materials and methods
Subject recruitment and assessment
Each data acquisition site (http://adni-info.org/images/
stories/map_of_adni_sites_feb2006.pdf) first obtained in-
stitutional review board approval before collecting any
data, and all subjects recruited gave informed written
consent. Inclusion/exclusion criteria for healthy controls
and AD subjects were similar to previous protocols
(http://www.adni-info.org/images/stories/Documentation/
adni_protocol_03.02.2005_ss.pdf) [16]. All MCI sub-
jects were amnestic and all AD subjects met standard
criteria for a diagnosis of AD (NINCDS-ADRDA
criteria for probable AD at baseline [17]). Each subject’s
diagnosis was reviewed at 6 months and 1 year.
Subjects were included in this study if they had baseline
and 12-month follow-up 1.5-T MR examination data
available by June 2008 and both MR examinations
passed standardised quality control. The MCI group
were subdivided into two subgroups: converters referred
to those subjects who progressed to meet criteria for AD
within the 12-month follow-up period, whereas stable
referred to those who maintained a diagnosis of
amnestic MCI.
Image acquisition
MR images were acquired with a standardised protocol
[18] on 1.5-T MRI units from Siemens Medical Solutions
and General Electric Healthcare. MR protocols included
high-resolution (typically 1.2×1.25×1.25 mm3 voxels)
volumetric T1-weighted, inversion recovery prepared, struc-
tural images obtained sagittally (http://www.adni-info.org/
images/stories//mritrainingmanualv1.pdf for more details).
Before the MR images were uploaded to the central image
repository, images were gradwarp-corrected for (a) distortion
due to gradient non-linearity [19], and (b) corrected for image
intensity non-uniformity using N3 [18, 20] (all images), and
B1 non-uniformity [18, 21] (where required, depending on
the coils used) and (c) scaling-corrected based on phantom
measures.
Semi-automated segmentation of brains
MR studies were downloaded from the website of the
Laboratory of NeuroImaging (LONI, http://www.loni.ucla.
edu/ADNI/) and transferred onto multiprocessor Intel
Xeon-based workstations running 32-bit Linux. The
image viewing and analysis software MIDAS [22] was
used for whole-brain and ventricular semi-automated
segmentation. Baseline whole-brain segmentation involved
a semi-automated technique with manual checking and
editing as necessary [22]. The intra-class correlation coef-
ficient for inter-rater reliability (ICC) was greater than 0.99
calculated from 11 people segmenting five subjects’ MR
data. The ICC values for intra-rater reliability were all greater
than 0.99 in 11 raters, segmenting five MR examinations
twice. Baseline brain regions were propagated onto
the follow-up MR data sets using affine and free-form
deformation-based non-rigid registration [23, 24].
Semi-automated segmentation of ventricles
Baseline and follow-up MR examinations were registered
to standard space (Montreal Neurological Institute 305
[25]) by estimating a nine-degrees of freedom (DoF)
transformation over the brain region [24] but only applying
the first six DoF (i.e. no scalings). An upper threshold of
60% of mean brain intensity was used to delineate the
ventricle region, including the whole of the lateral
ventricles and temporal horn, with manual editing
performed where necessary.
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Boundary shift integral
For both brains and ventricles, the follow-up MR data and
region were registered to the baseline using a nine-DoF
transformation [24]. Brains were then differentially bias-
corrected [26] and then both whole-brain (BBSI) and
ventricular (VBSI) BSIs were calculated [6]. BBSI was
expressed as an atrophy rate: annualised percentage change
in brain volume; VBSI was expressed as annualised
ventricular expansion in millilitres as ventricles can not
expand infinitely and normal variation in volumes is large,
making assessment of these changes on an absolute scale
more appropriate [14].
Psychological data
All subjects received a battery of psychological testing at
baseline and 12 months. Only the mini mental state
examination (MMSE) [27], the Alzheimer’s disease
assessment scale–cognitive subsection (ADAS-cog) [28]
and trails-making (A and B) [29] measures were considered
and assessed in this study. The MMSE is a commonly
reported measure of global cognitive function and is
marked out of 30, with a score of 24 or less being consistent
with mild AD. ADAS-cog is a composite global measure of
cognitive function marked out of 70, with a high score
being indicative of a greater deficit. By contrast, trails A
and B are tests where subjects are required to join either
consecutive numbers with a line (1–2–3–4 etc., part A) or
consecutive numbers and letters (1–A–2–B–3–C etc., part
B). Part A tests functions including visual search, speed of
search, and processing of sequences, whereas part B
includes the additional complexity of set-switching.
Annual changes in neuropsychology scores were calculated
as the change in score divided by the time between baseline
and 12-month follow-up.
Statistical analysis
All statistical analysis was performed using STATAversion
10. One-way ANCOVA was used to test whether
percentage change in whole-brain volume (on a logarith-
mic scale) and ventricular expansion (on an arithmetic
scale) differed by patient group (controls, MCI and AD),
accounting for age, gender and baseline volume. No
adjustment for premorbid brain size was made to brain
volume owing to this being used as a covariate only. To
account for unequal variances, robust standard errors were
used. Post hoc pairwise tests were applied to compare
patient groups.
One-way ANCOVA was also used to investigate
group differences in annualised change scores from each
of the neuropsychological tests (MMSE, ADAS-cog,
trails A and B), similarly adjusted for baseline, age and
gender and with robust standard errors. Ceiling effects
in MMSE and trails A and B were also accounted for
using binary indicators for those with baseline ceiling
scores and those increasing to ceiling at follow-up. No
individuals had ceiling scores in ADAS-cog at baseline
or follow-up. No individuals reached floor scores in any
cognitive measure at baseline or follow-up although two
subjects who had a score of “0” in trails B were treated
as having missing values.
Multivariable linear regression was used to investigate
the relationship between change in the neuropsychological
test scores (incorporating jump to ceiling) and brain
atrophy rates and ventricular expansion. These analyses
were performed separately by patient group adjusted for
baseline volume, baseline neuropsychological score, age,
gender and ceiling effects.
Differences in brain atrophy rates and ventricular
enlargement between those MCI subjects who converted
to AD within the period between MR examinations and
those who did not were investigated with a regression
model, adjusting for baseline volumes, age and gender and
with robust standard errors.
Results
Subjects included
All MR studies received by June 2008 (120 AD, 275 MCI
and 163 controls) were reviewed for quality; 21 AD, 40
MCI and 32 control subjects were excluded (controls=
19.6%, MCI=14.6%, AD=17.5%; p=0.4) due to motion
artefact or poor MR data set pair quality. This left 99 AD
subjects with a mean (standard deviation, SD) age of 75.3
(6.9) years; 235 MCI subjects aged 74.4 (7.1) years and
131 controls aged 76.0 (5.1) years; there was some
evidence of a difference over all groups in terms of age
(p=0.08) and gender (p=0.009), with a higher male
proportion in the MCI group (see Table 1 for subject
group demographics).
Table 2 and Fig. 1 show brain atrophy rates and
ventricular expansion in the three groups. Both measures
show control < MCI < AD with considerably less between-
subject variation in the control group.
Annualised brain atrophy rates (% change/year,
p<0.0005) and ventricular enlargement (p<0.0005) dif-
fered between controls, MCI and AD subjects, after
adjusting for baseline volumes, age and gender. In these
models there was no evidence of an effect of gender on
brain atrophy (p=0.9) or ventricular expansion (p=0.3);
however, there was evidence for increasing age to be
associated with lower whole-brain atrophy (p=0.04) and
ventricular expansion (p<0.0005) rates. There was some
evidence of a qualitative interaction between age and group
(p<0.05, joint interaction tests) with group differences
decreasing with age, but these effects were not large.
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Psychological data
Table 2 shows baseline and 0–12 month change for the
MMSE, ADAS-cog and trails A and B scores in the three
groups. There was strong evidence for a difference in
change scores adjusted for baseline score, age and gender
(and baseline ceiling scores for MMSE and trails measures)
in all cognitive measures for controls compared with
MCI subjects (MMSE p<0.0005, ADAS-cog p<0.0005,
trails-A p<0.0005, trails-B p<0.0005) and for controls
compared with AD patients (MMSE p<0.0005, ADAS-
cog p<0.0005, trails-A p<0.0005, trails-B p<0.0005).
There was also evidence for a difference between MCI and
AD patients in MMSE change scores (p=0.01), ADAS-cog
(p<0.0005) and trails-B (p<0.0005), but not trails-A
(p=0.1).
Associations between atrophy rates and cognitive
measures
There was strong evidence for an association between brain
atrophy rates and change in MMSE in both MCI
(p<0.0005) and AD (p=0.002) patients. There was also
strong evidence for an association between brain atrophy
and ADAS-cog change in MCI (p=0.0001) and borderline
evidence in AD (p=0.06) patients. There was no evidence
of an association between brain atrophy rates and trails A
change in MCI (p=0.2) or AD (p=0.2), and whilst there
was an association between brain atrophy rates and trails B
in MCI (p<0.0005), there was no evidence of association
in AD (p=0.4).
There was strong evidence for an association between
ventricular expansion and MMSE change in MCI
Table 1 Baseline information by patient group
MCI
Controls Non-converters Converters All MCI AD
N 131 188 43 231 99
Age, years (mean (SD)) 76.0 (5.1) 74.4 (7.2) 74.5 (6.4) 74.4 (7.1) 75.3 (6.9)
% male 47 63 60 63 51
MMSE (mean (SD)) 29.2 (1.0) 27.0 (1.8) 26.6 (1.8) 27.0 (1.8) 23.5 (1.8)
ADAS-cog (mean (SD)) 5.9 (3.0) 11.1 (4.1) 13.6 (4.9) 11.6 (4.4) 18.0 (6.0)b
Trails-A (median (IQR)) 33 (28, 42) 37 (30, 47) 45 (35, 56) 38 (31, 49) 53 (41, 81)
Trails-B (median (IQR)) 77 (60, 97) 102 (73, 153)a 133 (87, 212) 105 (75, 162) 186 (112, 300)c
Brain volume, ml (mean (SD)) 1,049 (103) 1,059 (117) 1,002 (85) 1,048 (114) 1,007 (111)
Ventricular volume, ml (mean (SD)) 38 (22) 45 (23) 52 (25) 46 (24) 52 (27)
IQR interquartile range
aMissing for four individuals
bMissing for one individual
cMissing for 17 individuals
Table 2 Raw change scores by patient group
MCI
Controls Non-converters Converters All MCI AD
N 131 188 43 231 99
Time to follow-up, years (mean (SD)) 1.07 (0.06) 1.07 (0.06) 1.04 (0.05) 1.07 (0.06) 1.07 (0.06)
MMSE change (mean (SD))a −0.02 (1.23) −0.02 (1.23) −2.06 (3.62) −0.85 (2.45) −2.06 (3.62)
ADAS-cog change (mean (SD))a −0.53 (2.70) 0.75 (4.06) 2.93 (4.94) 1.16 (4.31) 3.53 (5.42)c
Trails-A change (mean (SD))a −1.9 (9.4) 2.3 (14.6) 1.2 (13.1) 2.1 (14.3) 4.0 (19.1)
Trails-B change (mean (SD))a −5.7 (33.4) 8.3 (48.8)b 33.1 (68.7) 13.0 (53.8) 32.0 (58.1)d
Brain atrophy, % loss per year (mean (SD))a 0.49 (0.59) 0.92 (0.83) 1.61 (1.08) 1.05 (0.92) 1.50 (0.92)
VBSI, ml expansion per year (mean (SD))a 1.30 (1.41) 2.77 (2.43) 4.51 (3.43) 3.09 (2.72) 4.40 (2.99)
aChange per year of follow-up
bMissing for four individuals
cMissing for one individual
dMissing for 17 individuals, including 2 with follow-up scores of 0 and 2 with follow-up scores of −1 (missing indicator)
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(p<0.0005) and AD (p=0.002). There was also strong
evidence for an association between ventricular expansion
and ADAS-cog change in MCI (p<0.0005) and AD
(p=0.008). There was no evidence of association between
ventricular expansion and trails A change in either MCI
(p=0.2) or AD (p=0.3); however, there was evidence for
an association between ventricular expansion and trails B
change in MCI (p=0.003), although no evidence in AD
(p=0.2).
MCI converters and non-converters
MCI converters had rates of brain atrophy (% change/year,
p<0.0005) and ventricular expansion (p=0.001) that were
both approximately 50% higher than non-converters (see
Table 2 and Fig. 2), after adjustment for baseline volumes,
age and gender. In these models there was no evidence of
an effect of gender on brain atrophy (p=0.4) or ventricular
expansion rates (p=0.6); however, there was borderline
evidence for increasing age to be associated with lower
whole-brain rates (p=0.06) and strong evidence for
increasing age to be associated with lower ventricular
expansion (p<0.0005) rates. There was no evidence
that group differences varied by age (p>0.05, interaction
tests).
MCI non-converters also differed from both controls
(brain atrophy rates (p<0.0005) and ventricular expansion
(p<0.0005)) and AD (brain atrophy rates (p<0.0005) and
ventricular expansion (p<0.0005)). MCI converters dif-
fered from controls (brain atrophy rates (p<0.0005) and
ventricular expansion (p<0.0005)) but not AD patients
(neither brain atrophy rates (p=0.6) or ventricular expansion
(p=0.9)).
Discussion
In this large multicentre study we found mean (SD) whole-
brain loss at 1.5%/year (0.9%) in AD to be approximately
three times higher than the control rates of 0.5%/year
(0.6%/year) in controls whilst the MCI group as a whole
had an intermediate rate of approximately 1.1%/year
(0.9%/year). Some studies have reported higher atrophy
rates for AD subjects although subjects were often more
severely affected at the time of imaging. For example,
O’Brien et al. reported a brain atrophy rate of 2.0%/year
(0.9%/year) in patients with a mean age of 75 and mean
MMSE of 16 [9]; Fox et al. reported a brain atrophy rate of
2.4%/year (1.1%/year) for a mean age of 65 and mean
MMSE of 20 [30]; Archer et al. reported a brain atrophy
rate of 1.8%/year (1.4%/year) for a mean age of 66 and
mean MMSE 21 [31]; Wang et al. reported a brain atrophy
rate of 2.4%/year (1.2%/year) for a mean age of 67 and
mean MMSE 20 [32]; Sluimer et al. reported a rate of
1.9%/year (0.9%/year) for a mean age of 67 years and
mean MMSE 22 [12]. The mean MMSE in ADNI is higher
than the studies reported above, as ADNI enrolled at an
early disease stage. Atrophy rate in early disease has been
reported to be lower and this rate increases with severity [5,
33–35]. Another study has reported a lower rate of atrophy
than our study; Jack et al. reported slow-progressing ADs
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Fig. 1 Whole-brain atrophy
rates (left) and ventricular
expansion rates (right), by
patient group (unadjusted for
baseline volumes)
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having a median (interquartile range) atrophy rate of 0.6%/
year (0.7%/year) and fast-progressing patients having an
atrophy rate of 1.4%/year (1.1%/year) [10].
Interestingly the MCI subjects who progressed to AD
during the follow-up had a brain atrophy rate of 1.6%/year
(1.1%/year) which was very similar to the AD group and
about twice that of the MCI subjects who did not
progress to AD 0.9%/year (0.8%/year). The MCI subjects
who did not progress had a higher brain atrophy rate than
controls, implying that some of these MCI subjects were
heading towards an AD atrophy rate. Jack et al. reported
differences in atrophy rates (median (interquartile range))
for stable vs. converting MCI subjects as 0.4%/year
(0.4%/year) and 0.8%/year (0.5%/year), respectively [10].
Another study reported an overall mean (SD) atrophy rate
in MCI of 0.7%/year (0.7%/year) [11]. One recent paper
has also demonstrated that because MCI atrophy rates
accelerate in those subjects who convert to AD the
calculated rate in converters in any study may therefore
be dependent upon proximity to conversion [5]. A further
paper has shown that higher whole-brain atrophy rates are
associated with an increased risk of converting to AD
from MCI [12].
In this study, rates of ventricular enlargement had a
similar relationship to whole brain: mean (SD) rate was
4.4 ml/year (3.0 ml/year) in AD patients which was just
over three times the rate of controls which was 1.3 ml/year
(1.4 ml/year). Rates in the MCI group were between control
and AD rates at 3.1 ml/year (2.7 ml/year). Many studies
report relative (as a percentage of baseline volume) rather
than absolute atrophy rates for ventricles; our rates using this
method were 10.4%/year (6.4%/year) in AD patients,
8.2%/year (8.0%/year) in MCI subjects and 3.9%/year
(4.8%/year) in controls. Reported rates of ventricular en-
largement in AD are varied, ranging from 4 to 10 ml/year.
Silbert et al. reported a ventricular change of 5.5 ml/year
(3.2 ml/year) for a mean age of 82 and final MMSE of
12 [36]; Schott et al. reported a ventricular change of
4.3 ml/year (2.4 ml/year) for a mean age 70 and MMSE
of 20 [37]; Kaye et al. reported a ventricular change of
9.9 ml/year (5.8 ml/year) in mild AD for a mean age of
76 and mean MMSE 22 [38]; Wang et al. reported a
ventricular change of 8.2 ml/year (no SD given) for a
mean age of 67 and mean MMSE of 19.6 [32]. Silbert
et al. included older subjects than our study and with a
much lower MMSE, yet reported ventricular rates that
are comparable [36]. Differences in reported rates may
relate to methodology, most importantly how much of
the ventricular system was included. In terms of MCI,
various rates of ventricular change have been noted, some
much lower than reported here; for example, Jack et al.
reported a ventricular change of 3.3%/year (2.3%/year) for a
mean follow-up age of 80 and mean follow-up MMSE of 26
[11]. This is consistent with rates that are lower than some of
our previous studies; this may be due to patients being more
mildly affected, but it is possible that a number of subjects do
not have AD.
We showed that in both MCI and AD groups, brain and
ventricular changes were associated with change over
12 months in both the MMSE and ADAS-cog measures
although this was borderline in brain rates with ADAS-cog
in AD, and these results are consistent with previous
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reports [10, 12, 15, 39–41]. The associations may be
explained by the nature of the neuropsychological tests:
both MMSE and ADAS-cog are tests of global functioning,
spanning many domains localised to multiple cerebral
regions in different lobes and sub-cortical structures, giving
a strong association with global atrophy measures. We did
not show any association with trails A or B scores for the
AD group and only for MCI with trails B. The trail-making
test is a more focal rather than global cognitive measure,
testing aspects of visual search, executive function and
attention, which are localised mainly to frontal (especially
pre-frontal) and parietal lobes. Furthermore, there was huge
variability in change in trails scores in all patient groups.
We also showed that both brain atrophy rates and
ventricular expansion were higher in MCI subjects that
converted within the follow-up period compared with those
that remained stable. MCI converters were very similar to
the clinically diagnosed AD group in terms of brain
atrophy rates and ventricular expansion, which along with
similar cognitive profiles (Table 1) shows AD-like presen-
tation before/during conversion. Together these results
suggest a gradual adoption of AD-type cerebral and
cognitive profile with advancing disease progression.
Non-converters were different from both AD and controls,
placing them between these two groups, presumably
reflecting that some subjects are further from conversion
or may not convert in the future.
The data presented here are from a large multicentre
cohort typical of those recruited into therapeutic trials. We
conclude that brain and ventricular atrophy rates were
higher in MCI than controls and higher in AD than MCI
although there remained overlap between groups, with a
similar pattern shown for baseline and change scores for
neuropsychology. A strong brain–behaviour relationship
was demonstrated by the associations of the neuropsycho-
logical variables with brain and ventricular change. Those
MCI subjects who converted to AD within 12 months of
baseline assessment had atrophy rates similar to AD
subjects. These findings suggest that MCI may be a useful
group for use in clinical trials to test the efficacy of putative
pharmacological agents, particularly if those subjects likely
to progress could be separated from those likely to remain
stable.
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